All News

Jan 05, 2012

David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director: Douglas Lind and Joshua Zelig also added to the firm's roster

SAN FRANCISCO, January 5, 2011—Burrill & Company is pleased to announce that David Wetherell, a veteran entrepreneur and venture capitalist, has joined the Burrill Venture Capital Group as a Managing Director. Along with Wetherell, Douglas Lind, MD, joined the firm as a Managing Director Read More...

Filed Under: GBP Capital News

Nov 14, 2011

Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer

Cleveland, OH. and Gaithersburg, MD. November 14, 2011 – University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protecti Read More...

Filed Under: GBP Capital News

Aug 17, 2011

Lentigen Vector Used in Landmark Cancer Clinical Study

University of Pennsylvania Researchers used a lentiviral vector designed and manufactured by Lentigen to genetically modify "Serial Killer" T-cells to obliterate tumors in patients with Chronic Lymphocytic Leukemia . Further information on this study can be found at: http://www.uph Read More...

Filed Under: GBP Capital News

Apr 11, 2011

MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute

SAN DIEGO, April 11, 2011/PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has re Read More...

Filed Under: GBP Capital News

Feb 01, 2011

FSS Receives Full Investigational Device Exemption (IDE) Approval for its FlexStent Femoropoliteal SE Stent System

EATONTOWN, NJ - (Business Wire) - Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption (IDE) approval for its FlexSt Read More...

Filed Under: GBP Capital News

Nov 15, 2010

GBP Capital and ON Capital China Announce China Collaboration

Private equity firms GBP Capital, of Greenwich, CT, and ON Capital China, of Hong Kong and Beijing, today announced a collaboration between their two firms, whereby ON Capital China will assist in introducing GBP Capital’s portfolio of life science companies, where appropriate, into Chi Read More...

Filed Under: GBP Capital News

Nov 03, 2010

Lentigen Awarded $1.2 Million By U.S. Government Under the Qualifying Therapeutic Discovery Project

Gaithersburg, MD, November 3, 2010 – Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protecti Read More...

Filed Under: GBP Capital News

Aug 17, 2010

MabVax Therapeutics Receives Small Business Innovation Research Program Award From The National Cancer Institute

San Diego, CA, August 17, 2010 -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Busines Read More...

Filed Under: Company News

Aug 10, 2010

MabVax Therapeutics Receives $1.1 Million Phase 2 Small Business Technology Transfer Program Award From The National Cancer Institute

San Diego, CA, August 10, 2010 -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 Read More...

Filed Under: GBP Capital News

Aug 09, 2010

Lentigen Awarded Phase II SBIR Grant for Clinical Development of TCR

Gaithersburg , MD, August 9, 2010 – Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a N Read More...

Filed Under: Company News

64 results:

1234...7>>